Open AccessPneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys
Author(s) -
Lassané Kaboré,
Tolulope Adebanjo,
Berthe Marie Njanpop-Lafourcade,
Soumeya Ouangraoua,
Félix Tarbangdo,
Bertrand Méda,
Velusamy Srinivasan,
Brice Bicaba,
Flavien Aké,
Lesley McGee,
Seydou Yaro,
Edouard Betsem,
Alain Gervaix,
Bradford D. Gessner,
Cynthia G. Whitney,
Jennifer C. Moïsi,
Chris Van Beneden
Publication year - 2021
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiab037
Subject(s) - carriage , medicine , pneumococcal conjugate vaccine , confidence interval , vaccination , population , pneumococcal infections , serotype , streptococcus pneumoniae , pediatrics , cross sectional study , pneumococcal vaccine , meningitis , immunology , environmental health , antibiotics , biology , microbiology and biotechnology , pathology
Burkina Faso, a country in Africa's meningitis belt, introduced 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, with 3 primary doses given at 8, 12 and 16 weeks of age. To assess whether the new PCV13 program controlled pneumococcal carriage, we evaluated overall and serotype-specific colonization among children and adults during the first 3 years after introduction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom